Gina Shaw

2 weeks ago | journals.lww.com | Gina Shaw

​Use of over-the-counter (OTC) analgesics—including both acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs)—after a traumatic brain injury (TBI) was significantly associated with improved concussion symptoms and recovery, according to new data presented at the AAN Annual Meeting in San Diego. The prospective cohort study of National Collegiate Athletic Association (NCAA) and military cadets also found that the OTC drugs led to a quicker return to play.

2 weeks ago | journals.lww.com | Gina Shaw

Modern hormonal contraceptives, which contain substantially lower doses of estrogen compared with earlier-generation high-dose combined oral contraceptives, are not associated with an increased risk of stroke and other vascular events in women with migraine, both with and without aura, according to findings presented at the AAN Annual Meeting in San Diego. The large study used data from a nationwide de-identified electronic health record  database.

2 weeks ago | journals.lww.com | Gina Shaw

​Inebilizumab (Uplizna), a monoclonal antibody targeting CD19+ B-cells, significantly improves disease severity in patients with generalized myasthenia gravis (MG), according to new findings from the MINT phase 3 clinical trial presented at the AAN Annual Meeting in San Diego.

2 weeks ago | journals.lww.com | Gina Shaw

​ Fremanezumab (Ajovy)—a calcitonin gene-related peptide agonist (CGRP)— is safe and effective for prevention of episodic migraine in children and adolescents as young as 6 years old, according to findings presented at the AAN 2025 Annual Meeting in San Diego, The multicenter, double-blind, parallel-group, phase 3 study—led by headache medicine specialist and child neurologist Andrew Hersey, MD, PhD, FAAN, endowed chair and director of the division of neurology at Cincinnati Children's...

3 weeks ago | journals.lww.com | Gina Shaw

Article In BriefA new approval for an oral therapy for a disease-modifying therapy for spinal muscular atrophy elicited discussion about whether oral therapies have changed the treatment landscape for neurogenetic disorders. Experts said the answer varies depending on the therapy and condition. The US Food and Drug Administration (FDA) has approved a new tablet form of Genentech's spinal muscular atrophy (SMA) treatment risdiplam (Evrysdi) for patients ages 2 and older.